Abstract
Introduction
Neoadjuvant chemoradiotherapy (CRT) in rectal cancer can result in significant tumour regression and it has been advocated that it reduces the risk of local recurrence [1 -4] , even after correctly performed total mesorectal excision (TME) as described by RJ Heald in 1982 [5] . This has resulted in the widespread use of CRT for rectal cancer and whereas some units apply it more sparingly for cancers that threaten the mesorectal fascia (MRF) or invade adjacent structures [6] , other units routinely use neoadjuvant CRT for all rectal cancers over cT2 or cN+ [7] . Increasing the interval between the end of neoadjuvant chemoradiotherapy (CRT) and surgery could improve the pathological complete response (pCR) rates, allow fulldose neoadjuvant chemotherapy, and select patients with a clinical complete response (cCR) for inclusion in a "watch & wait" program (W&W) A significant proportion of patients receiving CRT will achieve pathological complete response (pCR), heralding an excellent prognosis due to low local and distant recurrence rates [8, 9] .
Several studies have shown that the rate of patients achieving pCR could be improved by increasing the interval between end of CRT and surgery Identifying clinical complete responders (cCR) that would be suitable for a W&W strategy is also a matter of rising interest [17] [18] [19] , adding to the rationale of waiting longer [20] . These cCR patients might benefit from non-operative management and intensive surveillance, avoiding permanent stomas, low anterior resection syndrome morbidity and adverse outcomes when quality of life issues are weighed [21] .
Finally, there is a growing body of evidence that some locally advanced rectal cancer (LARC) patients might benefit from full neoadjuvant chemotherapy. With this in mind, the canonical 6-8 weeks waiting period after RT might not be enough to administer a full dose of induction or consolidation chemotherapy regimens [22 -24].
However, there is no consensus on the optimal timing to operate [25]. Surgeons have been historically reluctant to delay surgery beyond 8 weeks as it might increase fibrosis around the TME plane, arguing that it could potentially lead to intra-operative technical difficulties and higher surgical morbidity.
While studies report that increasing the time interval to 8 weeks increased pCR rate without affecting patient morbidity [11, 26, 27], the GRECCAR-6 trial [28] showed that waiting until 11 weeks after CRT did not increase pCR after surgical resection and was associated with higher morbidity and worse specimen quality. Nevertheless, a recent population based study did not confirm the French observations [29].
The aim of this study was to compare short-term outcomes of rectal cancer surgery after an interval of less than 12 weeks after neoadjuvant CRT versus a longer interval.
Methods:
Consecutive patients from three centres (two in the UK, one in Portugal) who underwent 
Peri-operative care
Formal oncological and physical assessment was taken by all patients prior to surgery. Preoperative staging was performed by colonoscopy or CT colonography, computed tomography (CT) of the chest, abdomen, pelvis and magnetic resonance imaging (MRI) of the pelvis.
All patient findings were discussed in the multidisciplinary team meeting before treatment commencement. Preoperative CRT was given to patients with high risk for local recurrence (threatened CRM ≤2mm or T4 in staging MRI).
Patients included in the study had surgery performed by three colorectal surgeons (AP is a UK Lapco™ trainer & robotic proctor, having taught TQ and NF): one surgeon in each centre in the UK and one surgeon in Portugal. Surgery was open, laparoscopic, or robotic. Applied surgical modality was based on surgeon discretion. Minimally invasive TME was performed in a standardized fashion as described previously [30, 31] . After pre-operative irradiation, all rectal resections with an anastomosis performed below the peritoneal reflection had a diverging ileostomy (or transverse colostomy) fashioned.
Post-operative care was standardised, with patients entering a routine enhanced recovery programme based on the one described by Kehlet and Wilmore [32] . Patients were discharged home per set criteria for discharge.
Outcome assessment
The baseline characteristics and surgical outcomes of patients that were operated <12 weeks and ≥12 weeks after finishing CRT were analysed. Data was collected prospectively. 
Patient selection
No specific pre-CRT selection criteria were used to decide whether patients were operated <12 or ≥12 weeks after finishing CRT. Decision on time to operate following CRT completion was based on a shared-decision making process, including patient's preferences and multidisciplinary team decision. One centre had an ongoing program of deferral of surgery and offered patients to enter a "watch and wait" approach in case of a cCR.
The 12 week cut-off point for group analysis was decided upon lack of surgical and shortterm outcomes data beyond this point, in published trials [11, 26-28]. Additionally, when considering a "Watch and Wait" surveillance program, the final decision of proposing this nonoperative management usually is taken at restaging around 12 weeks. 
Statistical analysis IBM SPSS version 22 (SPSS

Results
Four hundred and seventy patients underwent rectal resection surgery by the three surgeons included in this study in three participating units. Neoadjuvant CRT was given to 124 (26%) of those patients, all of whom were included in the study. Seventy-six patients (61%) were operated ≥12 weeks after end of CRT and 48 (39%) <12 weeks, as shown in the histogram - Figure 1 . Median interval between CRT and surgery was 7 [6, 11] weeks for the first group, and 15 [12, 100] weeks for the latter.
Baseline characteristics
The baseline characteristics of the two groups are summarised in 
Peri-operative characteristics and outcomes
The peri-operative characteristics of the two groups are summarised in table 2. Operative time, estimated blood loss and conversion rate were not different. The majority of the operations were performed laparoscopically in both groups and there were no differences between the two groups in terms of surgical approach and procedure.
Post-operative clinical and pathological outcomes
The post-operative characteristics of the two groups are summarised in Due to this shift of treatment paradigm in rectal cancer, surgery is sometimes being delayed longer and longer, as represented in Figure 1 . This long tail in the histogram is due to the time inherently needed to take decisions in a "Watch & Wait" program:
to operate a non-responder; or to operate a local "regrowth" after a clinical complete response.
In the present study we found no difference in the short term surgical outcomes, and morbidity and mortality, between patients operated before or after 12 weeks following CRT. The finding of a slightly higher BMI at the time of surgery (27 vs 25) in the ≥12 weeks cohort could either be a chance finding, or could be related to patients having more time to recover and regain any weight loss after CRT.
Although the 3 surgeons performed a standardized TME, patients in the ≥12 week group had a lower lymph node yield (14 vs 11, p=0.001). Hypothetically this could be the delayed effect of CRT, in which increasing interval has an incremental effect on inducing fibrosis in lymphatic structures. However, this finding is not supported by any other studies [27, 28, 33] .
It is also worth mentioning that the anastomotic leak rate appears to be higher in the over 12 weeks cohort (0 vs 5.7%; p=0.547). Even though we recognize the chance of a type two error due to the limited sample size of the study, the p value indicates that there is an over 50% that this finding might be due to chance.
The GRECCAR-6 trial [28] is the only randomized trial, comparing a 7 vs 11 week interval after CRT in 265 patients. The trial reports an increased postoperative morbidity for the longer interval (44.5% vs 32%, p=0.04) and worse quality of mesorectal resection (complete mesorectum 78.7% vs 90%, p=0.016). Sphincter preservation, anastomotic leak and re-intervention rates were similar between the two groups. The reported increased morbidity was primarily due to medical complications, such as urinary complications, and were mostly relatively minor (Dindo II), not requiring re-intervention or a longer length of stay. In our study, delaying ≥12 weeks did not affect morbidity and anastomotic leak rates, translating into a similar 30-day reoperation, length of hospital stay and 30-day readmission rate. A possible explanation in this result discrepancy regarding morbidity might be that although in the GRECCAR-6 trial overall morbidity was higher in the 11-week group, this was primarily due to medical complications and specifically urinary complications, which did not affect re-intervention rate or length of stay. In fact, looking at the Dindo classification, only Dindo II complications were higher in the 11-week group, with Dindo III, IV and V being higher in the 7-week group. Considering that our dataset focuses on Dindo IIIb or above complications, or complications resulting in a readmission, this might justify the difference in terms of reported morbidity. A 2016 meta-analysis of the available (non-randomized) series reported for the longer interval group no difference in R0 resection rate, DFS or surgical complications, and an increase in pCR.
[14]
Another study compared the short-term outcomes of an increasing number of extra cycles of chemotherapy (mFOLFOX6) after conventional neo-adjuvant CRT and before TME [33] . The study consisted of four groups, with the control group receiving surgery 6-8 weeks after CRT, and the three experimental groups having a median delay time of 11.1, 15.4 and 19.3 weeks after CRT respectively.
The rate of pCR increased with a longer delay (18% vs 25% vs 30% vs 38%, p=0.0036), without affecting reported technical difficulty, blood loss, R0 rate, anastomotic leak rate and overall post-operative complication rate. Although the report describes an increased rate of pelvic fibrosis on a subjective fibrosis scale, this did not lead to an increased perceived difficulty as judged by the surgeons, and was not associated with postoperative complications.
In the context of delaying surgery, it is worth mentioning the results of the Stockholm III trial and will require TME surgery after an interval of more than 12 weeks. One of the concerns of surgeons with this approach is that delayed TME surgery might become more difficult.
The results of our study document that even when surgery is performed beyond the canonical 6-8 weeks period, patients are not hindered by an increase in LOS, 30-day readmission, 30-day reoperation, or 30-day mortality. In terms of surrogate oncologic outcomes, we did not observe a difference in CRM clearance, despite a lower lymph node yield in the delayed surgery group.
The limitations of the present study are related to the retrospective design and the possible selection bias in the short and long delay groups. Although retrospective, the data was collected from prospectively maintained databases, minimizing observation bias, and all consecutive patients were included to minimize selection bias. Furthermore, compared to GRECCAR-6 trial [28] a smaller number of patients were included in our study, increasing the risk of type 2 error in any of the outcomes.
Another limitation is that we have not reported minor post-operative complications (Clavien-Dindo I-II). This is because on our data sets we only record complications that result in reoperation (ClavienDindo grade IIIb or more) or complications resulting in a readmission. As a result, minor complications (Clavien-Dindo grade I-II) or complications of resulting in reintervention (Clavien-Dindo grade IIIa) are not recorded unless leading to a readmission. It is conceivable that the complications (Clavien-Dindo grade I-IIIa) would be reflected in a prolonged hospital stay or higher readmission rate, which was not the case in this study. However, we do recognize that these complications may have significant consequences in the patient's quality of life, without necessary leading to a higher length of stay or readmission rate.
In summary, our study shows that delaying surgery after CRT by more than 12 weeks does not seem to compromise the short-term surgical outcome. In the context of organ preservation with a W&W policy it seems therefore logical to extend the observation interval to delay surgery to ≥12 weeks in patients with a good response to CRT. This allows a better assessment of the tumour biology and the healing of the bowel wall. More patients will become eligible for organ preservation and will retain a better quality of life by avoiding major surgery. Further research with larger sample sized studies are required to throw further light into whether delaying surgery after CRT affects the short-term surgical outcomes of rectal cancer patients. Furthermore, it is important for future studies to investigate the functional outcomes of patients having delayed vs non-delayed surgery following CRT. This is an area were there is very little evidence and could be an important deciding factor when consulting patients whether to delay or not delay their surgery.
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Stengths:
This study adds to the existing literature examining the safety of delaying surgery after CRT and is of special interest since it is a surgical cohort of patients operated according to a standardized TME technique that stretches the delay period to more than 12 weeks.
Limitations:
Our study is not a randomized controlled trial, adding potential bias to the selection of patients in the two groups. We were not able to collect the reason for delay in all patients.
